NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Interesting that Novocure chose PFS as the Primary endpoint in their Phase 3 trial, with OS as the secondary endpoint. Evidently the right choice for them, with no pseudo progression issues that can characterise immunotherapies.

I guess Optune could be adopted as part of SOC on the basis of significant but small improvements in PFS and OS (a few months).Though their trial wasn't blinded, which I guess should mean that their data should have been considered slightly less significant. No claims are made about Optune having any curative capacity, or the ability to engender stable disease.

I guess that's the nature of SOC. It remains the same until something superior comes along...